Safety, Pharmacokinetic, and Efficacy Studies of Oral DB868 in a First Stage Vervet Monkey Model of Human African Trypanosomiasis
There are no oral drugs for human African trypanosomiasis (HAT, sleeping sickness). A successful oral drug would have the potential to reduce or eliminate the need for patient hospitalization, thus reducing healthcare costs of HAT. The development of oral medications is a key objective of the Consor...
Saved in:
| Published in | PLoS neglected tropical diseases Vol. 7; no. 6; p. e2230 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Public Library of Science
01.06.2013
Public Library of Science (PLoS) |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1935-2735 1935-2727 1935-2735 |
| DOI | 10.1371/journal.pntd.0002230 |
Cover
| Abstract | There are no oral drugs for human African trypanosomiasis (HAT, sleeping sickness). A successful oral drug would have the potential to reduce or eliminate the need for patient hospitalization, thus reducing healthcare costs of HAT. The development of oral medications is a key objective of the Consortium for Parasitic Drug Development (CPDD). In this study, we investigated the safety, pharmacokinetics, and efficacy of a new orally administered CPDD diamidine prodrug, 2,5-bis[5-(N-methoxyamidino)-2-pyridyl]furan (DB868; CPD-007-10), in the vervet monkey model of first stage HAT. DB868 was well tolerated at a dose up to 30 mg/kg/day for 10 days, a cumulative dose of 300 mg/kg. Mean plasma levels of biomarkers indicative of liver injury (alanine aminotransferase, aspartate aminotransferase) were not significantly altered by drug administration. In addition, no kidney-mediated alterations in creatinine and urea concentrations were detected. Pharmacokinetic analysis of plasma confirmed that DB868 was orally available and was converted to the active compound DB829 in both uninfected and infected monkeys. Treatment of infected monkeys with DB868 began 7 days post-infection. In the infected monkeys, DB829 attained a median C(max) (dosing regimen) that was 12-fold (3 mg/kg/day for 7 days), 15-fold (10 mg/kg/day for 7 days), and 31-fold (20 mg/kg/day for 5 days) greater than the IC50 (14 nmol/L) against T. b. rhodesiense STIB900. DB868 cured all infected monkeys, even at the lowest dose tested. In conclusion, oral DB868 cured monkeys with first stage HAT at a cumulative dose 14-fold lower than the maximum tolerated dose and should be considered a lead preclinical candidate in efforts to develop a safe, short course (5-7 days), oral regimen for first stage HAT. |
|---|---|
| AbstractList | There are no oral drugs for human African trypanosomiasis (HAT, sleeping sickness). A successful oral drug would have the potential to reduce or eliminate the need for patient hospitalization, thus reducing healthcare costs of HAT. The development of oral medications is a key objective of the Consortium for Parasitic Drug Development (CPDD). In this study, we investigated the safety, pharmacokinetics, and efficacy of a new orally administered CPDD diamidine prodrug, 2,5-bis[5-(N-methoxyamidino)-2-pyridyl]furan (DB868; CPD-007-10), in the vervet monkey model of first stage HAT. DB868 was well tolerated at a dose up to 30 mg/kg/day for 10 days, a cumulative dose of 300 mg/kg. Mean plasma levels of biomarkers indicative of liver injury (alanine aminotransferase, aspartate aminotransferase) were not significantly altered by drug administration. In addition, no kidney-mediated alterations in creatinine and urea concentrations were detected. Pharmacokinetic analysis of plasma confirmed that DB868 was orally available and was converted to the active compound DB829 in both uninfected and infected monkeys. Treatment of infected monkeys with DB868 began 7 days post-infection. In the infected monkeys, DB829 attained a median C(max) (dosing regimen) that was 12-fold (3 mg/kg/day for 7 days), 15-fold (10 mg/kg/day for 7 days), and 31-fold (20 mg/kg/day for 5 days) greater than the IC50 (14 nmol/L) against T. b. rhodesiense STIB900. DB868 cured all infected monkeys, even at the lowest dose tested. In conclusion, oral DB868 cured monkeys with first stage HAT at a cumulative dose 14-fold lower than the maximum tolerated dose and should be considered a lead preclinical candidate in efforts to develop a safe, short course (5-7 days), oral regimen for first stage HAT. There are no oral drugs for human African trypanosomiasis (HAT, sleeping sickness). A successful oral drug would have the potential to reduce or eliminate the need for patient hospitalization, thus reducing healthcare costs of HAT. The development of oral medications is a key objective of the Consortium for Parasitic Drug Development (CPDD). In this study, we investigated the safety, pharmacokinetics, and efficacy of a new orally administered CPDD diamidine prodrug, 2,5-bis[5-(N-methoxyamidino)-2- pyridyl]furan (DB868; CPD-007-10), in the vervet monkey model of first stage HAT. DB868 was well tolerated at a dose up to 30 mg/kg/day for 10 days, a cumulative dose of 300 mg/kg. Mean plasma levels of biomarkers indicative of liver injury (alanine aminotransferase, aspartate aminotransferase) were not significantly altered by drug administration. In addition, no kidney-mediated alterations in creatinine and urea concentrations were detected. Pharmacokinetic analysis of plasma confirmed that DB868 was orally available and was converted to the active compound DB829 in both uninfected and infected monkeys. Treatment of infected monkeys with DB868 began 7 days post-infection. In the infected monkeys, DB829 attained a median [C.sub.max] (dosing regimen) that was 12-fold (3 mg/kg/day for 7 days), 15-fold (10 mg/kg/day for 7 days), and 31-fold (20 mg/kg/day for 5 days) greater than the [IC.sub.50] (14 nmol/L) against T. b. rhodesiense STIB900. DB868 cured all infected monkeys, even at the lowest dose tested. In conclusion, oral DB868 cured monkeys with first stage HAT at a cumulative dose 14-fold lower than the maximum tolerated dose and should be considered a lead preclinical candidate in efforts to develop a safe, short course (5-7 days), oral regimen for first stage HAT. There are no oral drugs for human African trypanosomiasis (HAT, sleeping sickness). A successful oral drug would have the potential to reduce or eliminate the need for patient hospitalization, thus reducing healthcare costs of HAT. The development of oral medications is a key objective of the Consortium for Parasitic Drug Development (CPDD). In this study, we investigated the safety, pharmacokinetics, and efficacy of a new orally administered CPDD diamidine prodrug, 2,5-bis[5-(N-methoxyamidino)-2-pyridyl]furan (DB868; CPD-007-10), in the vervet monkey model of first stage HAT. DB868 was well tolerated at a dose up to 30 mg/kg/day for 10 days, a cumulative dose of 300 mg/kg. Mean plasma levels of biomarkers indicative of liver injury (alanine aminotransferase, aspartate aminotransferase) were not significantly altered by drug administration. In addition, no kidney-mediated alterations in creatinine and urea concentrations were detected. Pharmacokinetic analysis of plasma confirmed that DB868 was orally available and was converted to the active compound DB829 in both uninfected and infected monkeys. Treatment of infected monkeys with DB868 began 7 days post-infection. In the infected monkeys, DB829 attained a median Cmax (dosing regimen) that was 12-fold (3 mg/kg/day for 7 days), 15-fold (10 mg/kg/day for 7 days), and 31-fold (20 mg/kg/day for 5 days) greater than the IC50 (14 nmol/L) against T. b. rhodesiense STIB900. DB868 cured all infected monkeys, even at the lowest dose tested. In conclusion, oral DB868 cured monkeys with first stage HAT at a cumulative dose 14-fold lower than the maximum tolerated dose and should be considered a lead preclinical candidate in efforts to develop a safe, short course (5-7 days), oral regimen for first stage HAT. Development of orally administered medicines for human African trypanosomiasis (HAT) would potentially reduce the need for patient hospitalization, thus lowering healthcare costs. In this study, we investigated the potential of a novel diamidine prodrug, DB868 (CPD-007-10), as an oral treatment for first stage HAT. When administered to uninfected monkeys by oral gavage, DB868 was well tolerated up to a maximum dose of 30 mg/kg/day for 10 days (cumulative dose [CD]=300 mg/kg). DB868 was absorbed into the systemic circulation and was converted to the active compound DB829 in concentrations that were potentially therapeutic for blood trypanosomes. Subsequently, DB868 was evaluated for efficacy in the first stage vervet monkey model of HAT in which treatment was initiated at 7 days post-infection with T. b. rhodesiense KETRI 2537. All infected monkeys were cured, even at the lowest of the three dose regimens tested: 3 mg/kg/day for 7 days (CD=21 mg/kg), 10 mg/kg/day for 7 days (CD=70 mg/kg) and 20 mg/kg/day for 5 days (CD=100 mg/kg). DB868 conversion to DB829 was comparable between uninfected and infected monkeys. In view of its favourable safety and oral efficacy profile, we conclude that DB868 is a suitable candidate for development as a new treatment for first stage HAT. There are no oral drugs for human African trypanosomiasis (HAT, sleeping sickness). A successful oral drug would have the potential to reduce or eliminate the need for patient hospitalization, thus reducing healthcare costs of HAT. The development of oral medications is a key objective of the Consortium for Parasitic Drug Development (CPDD). In this study, we investigated the safety, pharmacokinetics, and efficacy of a new orally administered CPDD diamidine prodrug, 2,5-bis[5-(N-methoxyamidino)-2-pyridyl]furan (DB868; CPD-007-10), in the vervet monkey model of first stage HAT. DB868 was well tolerated at a dose up to 30 mg/kg/day for 10 days, a cumulative dose of 300 mg/kg. Mean plasma levels of biomarkers indicative of liver injury (alanine aminotransferase, aspartate aminotransferase) were not significantly altered by drug administration. In addition, no kidney-mediated alterations in creatinine and urea concentrations were detected. Pharmacokinetic analysis of plasma confirmed that DB868 was orally available and was converted to the active compound DB829 in both uninfected and infected monkeys. Treatment of infected monkeys with DB868 began 7 days post-infection. In the infected monkeys, DB829 attained a median C(max) (dosing regimen) that was 12-fold (3 mg/kg/day for 7 days), 15-fold (10 mg/kg/day for 7 days), and 31-fold (20 mg/kg/day for 5 days) greater than the IC50 (14 nmol/L) against T. b. rhodesiense STIB900. DB868 cured all infected monkeys, even at the lowest dose tested. In conclusion, oral DB868 cured monkeys with first stage HAT at a cumulative dose 14-fold lower than the maximum tolerated dose and should be considered a lead preclinical candidate in efforts to develop a safe, short course (5-7 days), oral regimen for first stage HAT.There are no oral drugs for human African trypanosomiasis (HAT, sleeping sickness). A successful oral drug would have the potential to reduce or eliminate the need for patient hospitalization, thus reducing healthcare costs of HAT. The development of oral medications is a key objective of the Consortium for Parasitic Drug Development (CPDD). In this study, we investigated the safety, pharmacokinetics, and efficacy of a new orally administered CPDD diamidine prodrug, 2,5-bis[5-(N-methoxyamidino)-2-pyridyl]furan (DB868; CPD-007-10), in the vervet monkey model of first stage HAT. DB868 was well tolerated at a dose up to 30 mg/kg/day for 10 days, a cumulative dose of 300 mg/kg. Mean plasma levels of biomarkers indicative of liver injury (alanine aminotransferase, aspartate aminotransferase) were not significantly altered by drug administration. In addition, no kidney-mediated alterations in creatinine and urea concentrations were detected. Pharmacokinetic analysis of plasma confirmed that DB868 was orally available and was converted to the active compound DB829 in both uninfected and infected monkeys. Treatment of infected monkeys with DB868 began 7 days post-infection. In the infected monkeys, DB829 attained a median C(max) (dosing regimen) that was 12-fold (3 mg/kg/day for 7 days), 15-fold (10 mg/kg/day for 7 days), and 31-fold (20 mg/kg/day for 5 days) greater than the IC50 (14 nmol/L) against T. b. rhodesiense STIB900. DB868 cured all infected monkeys, even at the lowest dose tested. In conclusion, oral DB868 cured monkeys with first stage HAT at a cumulative dose 14-fold lower than the maximum tolerated dose and should be considered a lead preclinical candidate in efforts to develop a safe, short course (5-7 days), oral regimen for first stage HAT. There are no oral drugs for human African trypanosomiasis (HAT, sleeping sickness). A successful oral drug would have the potential to reduce or eliminate the need for patient hospitalization, thus reducing healthcare costs of HAT. The development of oral medications is a key objective of the Consortium for Parasitic Drug Development (CPDD). In this study, we investigated the safety, pharmacokinetics, and efficacy of a new orally administered CPDD diamidine prodrug, 2,5-bis[5-( N -methoxyamidino)-2-pyridyl]furan (DB868; CPD-007-10), in the vervet monkey model of first stage HAT. DB868 was well tolerated at a dose up to 30 mg/kg/day for 10 days, a cumulative dose of 300 mg/kg. Mean plasma levels of biomarkers indicative of liver injury (alanine aminotransferase, aspartate aminotransferase) were not significantly altered by drug administration. In addition, no kidney-mediated alterations in creatinine and urea concentrations were detected. Pharmacokinetic analysis of plasma confirmed that DB868 was orally available and was converted to the active compound DB829 in both uninfected and infected monkeys. Treatment of infected monkeys with DB868 began 7 days post-infection. In the infected monkeys, DB829 attained a median C max (dosing regimen) that was 12-fold (3 mg/kg/day for 7 days), 15-fold (10 mg/kg/day for 7 days), and 31-fold (20 mg/kg/day for 5 days) greater than the IC 50 (14 nmol/L) against T. b. rhodesiense STIB900. DB868 cured all infected monkeys, even at the lowest dose tested. In conclusion, oral DB868 cured monkeys with first stage HAT at a cumulative dose 14-fold lower than the maximum tolerated dose and should be considered a lead preclinical candidate in efforts to develop a safe, short course (5–7 days), oral regimen for first stage HAT. Development of orally administered medicines for human African trypanosomiasis (HAT) would potentially reduce the need for patient hospitalization, thus lowering healthcare costs. In this study, we investigated the potential of a novel diamidine prodrug, DB868 (CPD-007-10), as an oral treatment for first stage HAT. When administered to uninfected monkeys by oral gavage, DB868 was well tolerated up to a maximum dose of 30 mg/kg/day for 10 days (cumulative dose [CD] = 300 mg/kg). DB868 was absorbed into the systemic circulation and was converted to the active compound DB829 in concentrations that were potentially therapeutic for blood trypanosomes. Subsequently, DB868 was evaluated for efficacy in the first stage vervet monkey model of HAT in which treatment was initiated at 7 days post-infection with T. b. rhodesiense KETRI 2537. All infected monkeys were cured, even at the lowest of the three dose regimens tested: 3 mg/kg/day for 7 days (CD = 21 mg/kg), 10 mg/kg/day for 7 days (CD = 70 mg/kg) and 20 mg/kg/day for 5 days (CD = 100 mg/kg). DB868 conversion to DB829 was comparable between uninfected and infected monkeys. In view of its favourable safety and oral efficacy profile, we conclude that DB868 is a suitable candidate for development as a new treatment for first stage HAT. There are no oral drugs for human African trypanosomiasis (HAT, sleeping sickness). A successful oral drug would have the potential to reduce or eliminate the need for patient hospitalization, thus reducing healthcare costs of HAT. The development of oral medications is a key objective of the Consortium for Parasitic Drug Development (CPDD). In this study, we investigated the safety, pharmacokinetics, and efficacy of a new orally administered CPDD diamidine prodrug, 2,5-bis[5-(N-methoxyamidino)-2-pyridyl]furan (DB868; CPD-007-10), in the vervet monkey model of first stage HAT. DB868 was well tolerated at a dose up to 30 mg/kg/day for 10 days, a cumulative dose of 300 mg/kg. Mean plasma levels of biomarkers indicative of liver injury (alanine aminotransferase, aspartate aminotransferase) were not significantly altered by drug administration. In addition, no kidney-mediated alterations in creatinine and urea concentrations were detected. Pharmacokinetic analysis of plasma confirmed that DB868 was orally available and was converted to the active compound DB829 in both uninfected and infected monkeys. Treatment of infected monkeys with DB868 began 7 days post-infection. In the infected monkeys, DB829 attained a median Cmax (dosing regimen) that was 12-fold (3 mg/kg/day for 7 days), 15-fold (10 mg/kg/day for 7 days), and 31-fold (20 mg/kg/day for 5 days) greater than the IC50 (14 nmol/L) against T. b. rhodesiense STIB900. DB868 cured all infected monkeys, even at the lowest dose tested. In conclusion, oral DB868 cured monkeys with first stage HAT at a cumulative dose 14-fold lower than the maximum tolerated dose and should be considered a lead preclinical candidate in efforts to develop a safe, short course (5-7 days), oral regimen for first stage HAT. |
| Audience | Academic |
| Author | Bridges, Arlene S. Hall, James Edwin Liu, Qiang Ismail, Mohamed A. Tidwell, Richard R. Chen, Yao Wang, Michael Zhuo Wolf, Kristina K. Ching, Shelley Mutuku, James N. Murilla, Grace A. Mdachi, Raymond E. Brun, Reto Paine, Mary F. Thuita, John K. Boykin, David W. |
| AuthorAffiliation | Institute of Tropical Medicine, Belgium 7 SVC Associates, Inc., Apex, North Carolina, United States of America 6 Department of Chemistry, Georgia State University, Atlanta, Georgia, United States of America 5 Department of Pathology and Laboratory Medicine, School of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America 4 Department of Pharmaceutical Chemistry, The University of Kansas, Lawrence, Kansas, United States of America 8 Swiss Tropical and Public Health Institute, Basel, Switzerland 2 University of Basel, Basel, Switzerland 1 Trypanosomiasis Research Centre, Kenya Agricultural Research Institute (KARI-TRC), Kikuyu, Kenya 3 UNC Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America |
| AuthorAffiliation_xml | – name: 6 Department of Chemistry, Georgia State University, Atlanta, Georgia, United States of America – name: Institute of Tropical Medicine, Belgium – name: 5 Department of Pathology and Laboratory Medicine, School of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America – name: 2 University of Basel, Basel, Switzerland – name: 4 Department of Pharmaceutical Chemistry, The University of Kansas, Lawrence, Kansas, United States of America – name: 8 Swiss Tropical and Public Health Institute, Basel, Switzerland – name: 3 UNC Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America – name: 7 SVC Associates, Inc., Apex, North Carolina, United States of America – name: 1 Trypanosomiasis Research Centre, Kenya Agricultural Research Institute (KARI-TRC), Kikuyu, Kenya |
| Author_xml | – sequence: 1 givenname: John K. surname: Thuita fullname: Thuita, John K. – sequence: 2 givenname: Kristina K. surname: Wolf fullname: Wolf, Kristina K. – sequence: 3 givenname: Grace A. surname: Murilla fullname: Murilla, Grace A. – sequence: 4 givenname: Qiang surname: Liu fullname: Liu, Qiang – sequence: 5 givenname: James N. surname: Mutuku fullname: Mutuku, James N. – sequence: 6 givenname: Yao surname: Chen fullname: Chen, Yao – sequence: 7 givenname: Arlene S. surname: Bridges fullname: Bridges, Arlene S. – sequence: 8 givenname: Raymond E. surname: Mdachi fullname: Mdachi, Raymond E. – sequence: 9 givenname: Mohamed A. surname: Ismail fullname: Ismail, Mohamed A. – sequence: 10 givenname: Shelley surname: Ching fullname: Ching, Shelley – sequence: 11 givenname: David W. surname: Boykin fullname: Boykin, David W. – sequence: 12 givenname: James Edwin surname: Hall fullname: Hall, James Edwin – sequence: 13 givenname: Richard R. surname: Tidwell fullname: Tidwell, Richard R. – sequence: 14 givenname: Mary F. surname: Paine fullname: Paine, Mary F. – sequence: 15 givenname: Reto surname: Brun fullname: Brun, Reto – sequence: 16 givenname: Michael Zhuo surname: Wang fullname: Wang, Michael Zhuo |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/23755309$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNUl1rFDEUHaRiP_QfiAYE8aG7ZpL5SHwQam1toVKh1deQSW52s51J1mSmsI_-czPuVnZFRAKTITnn3HtPzmG257yDLHue42lO6_ztwg_ByXa6dL2eYowJofhRdpBzWk5ITcu9rf_97DDGBcYlL1n-JNsntC5LivlB9uNGGuhXx-jLXIZOKn9nHfRWHSPpNDozxiqpVuimH7SFiLxB10G26OMHVjFkHZLo3IbYJ4CcAfoG4R569Nm7O1ilTUM7Ui6GTjp0YkISc-g2rJbS-eg7K6ONT7PHRrYRnm32o-zr-dnt6cXk6vrT5enJ1URVhPeTymCdFwYY0bmpap0zUuMG16wwGtKnUDVTqmkkB2AKM8KVLGSR2mRl1dSGHmUv17rL1kexcS-KvMA4pxUjRUJcrhHay4VYBtvJsBJeWvHrwIeZkCF504KglPCGNpgy3RQqN00qbBRpoKCV1BqS1vtNtaHpQCtwffJtR3T3xtm5mPl7Qau64LxMAm82AsF_HyD2orNRQdtKB35IfVPOeXpHzv8DWqX5MK_HEV-toTOZprDO-FRcjXBxQmlNGMP1WHv6F1RaGjqrUgyNTec7hNdbhDnItp9H3w699S7uAl9s2_Lbj4dAJsC7NUAFH2MAI5Tt5aiTWrCtyLEY0__wfmJMv9ikP5GLP8gP-v-k_QR_XQtD |
| CitedBy_id | crossref_primary_10_1002_ardp_202100385 crossref_primary_10_1002_jps_23765 crossref_primary_10_4155_fmc_13_162 crossref_primary_10_1128_AAC_00122_14 crossref_primary_10_1039_C7MD00280G crossref_primary_10_1016_j_ejmech_2014_04_079 crossref_primary_10_2174_1385272823666191029114830 crossref_primary_10_1371_journal_pntd_0003409 crossref_primary_10_1080_21691401_2019_1596923 crossref_primary_10_1515_zpch_2023_0207 crossref_primary_10_1039_D0RA08796C crossref_primary_10_1111_jmp_12201 crossref_primary_10_1080_00397911_2020_1776877 crossref_primary_10_1128_AAC_00398_13 |
| Cites_doi | 10.1017/S0031182010001137 10.1371/journal.pntd.0000906 10.1080/00498250500087671 10.1111/j.1365-3156.2005.01470.x 10.1371/journal.pntd.0000238 10.1016/j.actatropica.2004.03.010 10.1083/jcb.85.3.501 10.1371/journal.pntd.0001734 10.1128/AAC.01551-10 10.1021/jm0302602 10.1016/S0140-6736(09)60829-1 10.2217/fmb.11.44 10.1172/JCI200421052 10.1128/AAC.00250-10 10.1021/jm030604o 10.1016/j.coph.2012.05.001 10.1124/jpet.110.177220 10.1124/dmd.106.010587 10.1128/AAC.00225-09 10.1124/dmd.112.048231 10.1016/S0960-894X(96)00557-4 10.1128/AAC.00831-08 10.1124/dmd.106.013391 10.3201/eid1602.090967 10.1016/j.biochi.2008.02.017 10.1093/toxsci/kfs238 10.1002/jms.591 |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2013 Public Library of Science 2013 Thuita et al 2013 Thuita et al 2013 Thuita et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited: Thuita JK, Wolf KK, Murilla GA, Liu Q, Mutuku JN, et al. (2013) Safety, Pharmacokinetic, and Efficacy Studies of Oral DB868 in a First Stage Vervet Monkey Model of Human African Trypanosomiasis. PLoS Negl Trop Dis 7(6): e2230. doi:10.1371/journal.pntd.0002230 |
| Copyright_xml | – notice: COPYRIGHT 2013 Public Library of Science – notice: 2013 Thuita et al 2013 Thuita et al – notice: 2013 Thuita et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited: Thuita JK, Wolf KK, Murilla GA, Liu Q, Mutuku JN, et al. (2013) Safety, Pharmacokinetic, and Efficacy Studies of Oral DB868 in a First Stage Vervet Monkey Model of Human African Trypanosomiasis. PLoS Negl Trop Dis 7(6): e2230. doi:10.1371/journal.pntd.0002230 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 C1K F1W H95 H97 L.G M7N 5PM DOA |
| DOI | 10.1371/journal.pntd.0002230 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic Environmental Sciences and Pollution Management ASFA: Aquatic Sciences and Fisheries Abstracts Aquatic Science & Fisheries Abstracts (ASFA) 1: Biological Sciences & Living Resources Aquatic Science & Fisheries Abstracts (ASFA) 3: Aquatic Pollution & Environmental Quality Aquatic Science & Fisheries Abstracts (ASFA) Professional Algology Mycology and Protozoology Abstracts (Microbiology C) PubMed Central (Full Participant titles) DOAJ (Directory of Open Access Journals) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic Aquatic Science & Fisheries Abstracts (ASFA) Professional Aquatic Science & Fisheries Abstracts (ASFA) 1: Biological Sciences & Living Resources Aquatic Science & Fisheries Abstracts (ASFA) 3: Aquatic Pollution & Environmental Quality Algology Mycology and Protozoology Abstracts (Microbiology C) ASFA: Aquatic Sciences and Fisheries Abstracts Environmental Sciences and Pollution Management |
| DatabaseTitleList | MEDLINE Aquatic Science & Fisheries Abstracts (ASFA) Professional MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| DocumentTitleAlternate | Pharmacology of Oral DB868 in a HAT Monkey Model |
| EISSN | 1935-2735 |
| ExternalDocumentID | 1400136824 oai_doaj_org_article_3329b3b038db4c1fbbbafc2be436adde PMC3674995 A337288075 23755309 10_1371_journal_pntd_0002230 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | Africa |
| GeographicLocations_xml | – name: Africa |
| GroupedDBID | --- 123 29O 2WC 53G 5VS 7X7 88E 8C1 8FI 8FJ AAFWJ AAUCC AAWOE AAYXX ABDBF ABUWG ACGFO ACIHN ACPRK ACUHS ADBBV ADRAZ AEAQA AENEX AEUYN AFKRA AFPKN AFRAH AHMBA ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV BENPR BPHCQ BVXVI BWKFM CCPQU CITATION CS3 DIK DU5 E3Z EAP EAS EBD ECGQY EMOBN ESX F5P FPL FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR IHW ITC KQ8 M1P M48 O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RNS RPM SV3 TR2 TUS UKHRP 3V. CGR CUY CVF ECM EIF H13 IPNFZ M~E NPM PV9 RIG RZL WOQ PMFND 7X8 PJZUB PPXIY PUEGO C1K F1W H95 H97 L.G M7N 5PM AAPBV ABPTK |
| ID | FETCH-LOGICAL-c629t-6f0d14fe82d1f67d18270b0784fde84f4c78ccbba9ee8c0829ca4a4868856b7f3 |
| IEDL.DBID | M48 |
| ISSN | 1935-2735 1935-2727 |
| IngestDate | Sun Oct 01 00:20:30 EDT 2023 Wed Aug 27 01:26:42 EDT 2025 Thu Aug 21 18:12:15 EDT 2025 Thu Sep 04 19:07:06 EDT 2025 Thu Sep 04 17:00:25 EDT 2025 Tue Jun 17 21:18:35 EDT 2025 Tue Jun 10 20:36:33 EDT 2025 Thu May 22 21:22:10 EDT 2025 Wed Feb 19 01:54:51 EST 2025 Tue Jul 01 03:40:47 EDT 2025 Thu Apr 24 23:09:46 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Language | English |
| License | This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. Creative Commons Attribution License |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c629t-6f0d14fe82d1f67d18270b0784fde84f4c78ccbba9ee8c0829ca4a4868856b7f3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 The authors have declared that no competing interests exist. Conceived and designed the experiments: MZW RB JEH MFP RRT. Performed the experiments: JKT KKW QL JNM YC ASB REM. Analyzed the data: JKT KKW GAM SC MFP RB MZW. Contributed reagents/materials/analysis tools: MAI DWB . Wrote the paper: JKT MZW. |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1371/journal.pntd.0002230 |
| PMID | 23755309 |
| PQID | 1366820974 |
| PQPubID | 23479 |
| ParticipantIDs | plos_journals_1400136824 doaj_primary_oai_doaj_org_article_3329b3b038db4c1fbbbafc2be436adde pubmedcentral_primary_oai_pubmedcentral_nih_gov_3674995 proquest_miscellaneous_1399923799 proquest_miscellaneous_1366820974 gale_infotracmisc_A337288075 gale_infotracacademiconefile_A337288075 gale_healthsolutions_A337288075 pubmed_primary_23755309 crossref_citationtrail_10_1371_journal_pntd_0002230 crossref_primary_10_1371_journal_pntd_0002230 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2013-06-01 |
| PublicationDateYYYYMMDD | 2013-06-01 |
| PublicationDate_xml | – month: 06 year: 2013 text: 2013-06-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: San Francisco, USA |
| PublicationTitle | PLoS neglected tropical diseases |
| PublicationTitleAlternate | PLoS Negl Trop Dis |
| PublicationYear | 2013 |
| Publisher | Public Library of Science Public Library of Science (PLoS) |
| Publisher_xml | – name: Public Library of Science – name: Public Library of Science (PLoS) |
| References | ref34 T Wenzler (ref12) 2009; 53 DH Greegor (ref19) 1972; 22 RE Mdachi (ref16) 2009; 53 JH Ansede (ref25) 2004; 47 MF Paine (ref11) 2010; 11 I Midgley (ref32) 2007; 35 JH Ansede (ref26) 2005; 35 N Borgese (ref30) 1980; 85 LM MacLean (ref4) 2010; 4 C Burri (ref7) 2010; 137 MZ Wang (ref22) 2010; 54 DW Boykin (ref28) 1996; 6 GZ Yan (ref31) 2011; 337 MZ Wang (ref17) 2006; 34 M Odiit (ref2) 2005; 10 CN Generaux (ref23) 2013; 41 P Maser (ref9) 2012; 12 R Brun (ref13) 2011; 6 L Zhou (ref27) 2004; 39 JK Thuita (ref20) 2012; 6 F Chappuis (ref3) 2010; 16 R Brun (ref1) 2010; 375 PT Woo (ref24) 1970; 27 ref6 (ref8); 17 LM Sturk (ref18) 2004; 91 JY Saulter (ref29) 2005; 33 AH Harrill (ref21) 2012; 130 CP Ward (ref33) 2011; 55 MA Ismail (ref14) 2003; 46 WD Wilson (ref10) 2008; 90 PG Kennedy (ref5) 2004; 113 JK Thuita (ref15) 2008; 2 20368397 - Antimicrob Agents Chemother. 2010 Jun;54(6):2507-16 15103648 - J Mass Spectrom. 2004 Apr;39(4):351-60 22940726 - Toxicol Sci. 2012 Dec;130(2):416-26 10070249 - World Health Organ Tech Rep Ser. 1998;881:I-VI, 1-114 4396363 - Acta Trop. 1970;27(4):384-6 17360833 - Drug Metab Dispos. 2007 Jun;35(6):955-67 14966556 - J Clin Invest. 2004 Feb;113(4):496-504 19064893 - Antimicrob Agents Chemother. 2009 Mar;53(3):953-7 20721830 - Curr Opin Investig Drugs. 2010 Aug;11(8):876-83 16135190 - Trop Med Int Health. 2005 Sep;10(9):840-9 21151878 - PLoS Negl Trop Dis. 2010;4(12):e906 7391131 - J Cell Biol. 1980 Jun;85(3):501-15 16019947 - Xenobiotica. 2005 Mar;35(3):211-26 15294005 - J Med Chem. 2004 Aug 12;47(17):4335-8 22848769 - PLoS Negl Trop Dis. 2012;6(7):e1734 20961469 - Parasitology. 2010 Dec;137(14):1987-94 4632237 - CA Cancer J Clin. 1972 Nov-Dec;22(6):360-3 22652215 - Curr Opin Pharmacol. 2012 Oct;12(5):562-6 19620327 - Antimicrob Agents Chemother. 2009 Oct;53(10):4185-92 16997912 - Drug Metab Dispos. 2006 Dec;34(12):1985-94 20113585 - Emerg Infect Dis. 2010 Feb;16(2):354-6 14561095 - J Med Chem. 2003 Oct 23;46(22):4761-9 22433595 - Euro Surveill. 2012;17(10). pii: 20111 21320872 - J Pharmacol Exp Ther. 2011 May;337(2):503-12 15234662 - Acta Trop. 2004 Jul;91(2):131-43 18343228 - Biochimie. 2008 Jul;90(7):999-1014 18846231 - PLoS Negl Trop Dis. 2008;2(5):e238 19833383 - Lancet. 2010 Jan 9;375(9709):148-59 23223498 - Drug Metab Dispos. 2013 Feb;41(2):518-28 16131524 - Drug Metab Dispos. 2005 Dec;33(12):1886-93 21402852 - Antimicrob Agents Chemother. 2011 May;55(5):2352-61 21707314 - Future Microbiol. 2011 Jun;6(6):677-91 |
| References_xml | – volume: 137 start-page: 1987 year: 2010 ident: ref7 article-title: Chemotherapy against human African trypanosomiasis: is there a road to success? publication-title: Parasitology doi: 10.1017/S0031182010001137 – volume: 4 start-page: e906 year: 2010 ident: ref4 article-title: Focus-specific clinical profiles in human African Trypanosomiasis caused by Trypanosoma brucei rhodesiense publication-title: PLoS Negl Trop Dis doi: 10.1371/journal.pntd.0000906 – volume: 35 start-page: 211 year: 2005 ident: ref26 article-title: In vitro metabolism of an orally active O-methyl amidoxime prodrug for the treatment of CNS trypanosomiasis publication-title: Xenobiotica doi: 10.1080/00498250500087671 – volume: 10 start-page: 840 year: 2005 ident: ref2 article-title: Quantifying the level of under-detection of Trypanosoma brucei rhodesiense sleeping sickness cases publication-title: Trop Med Int Health doi: 10.1111/j.1365-3156.2005.01470.x – volume: 2 start-page: e238 year: 2008 ident: ref15 article-title: Trypanosoma brucei rhodesiense transmitted by a single tsetse fly bite in vervet monkeys as a model of human African trypanosomiasis publication-title: PLoS Negl Trop Dis doi: 10.1371/journal.pntd.0000238 – volume: 22 start-page: 360 year: 1972 ident: ref19 article-title: Detection of colorectal cancer using guaiac slides publication-title: CA: A Cancer Journal for Clinicians – volume: 91 start-page: 131 year: 2004 ident: ref18 article-title: Distribution and quantitation of the anti-trypanosomal diamidine 2,5-bis(4-amidinophenyl)furan (DB75) and its N-methoxy prodrug DB289 in murine brain tissue publication-title: Acta Trop doi: 10.1016/j.actatropica.2004.03.010 – volume: 85 start-page: 501 year: 1980 ident: ref30 article-title: Localization and biosynthesis of NADH-cytochrome b5 reductase, an integral membrane protein, in rat liver cells. I. Distribution of the enzyme activity in microsomes, mitochondria, and golgi complex publication-title: J Cell Biol doi: 10.1083/jcb.85.3.501 – volume: 6 start-page: e1734 year: 2012 ident: ref20 article-title: Pharmacology of DB844, an orally active aza analogue of pafuramidine, in a monkey model of second stage human African trypanosomiasis publication-title: PLoS Negl Trop Dis doi: 10.1371/journal.pntd.0001734 – volume: 55 start-page: 2352 year: 2011 ident: ref33 article-title: Trypanocidal furamidine analogues: influence of pyridine nitrogens on trypanocidal activity, transport kinetics, and resistance patterns publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.01551-10 – volume: 46 start-page: 4761 year: 2003 ident: ref14 article-title: Synthesis and antiprotozoal activity of aza-analogues of furamidine publication-title: J Med Chem doi: 10.1021/jm0302602 – volume: 375 start-page: 148 year: 2010 ident: ref1 article-title: Human African trypanosomiasis publication-title: Lancet doi: 10.1016/S0140-6736(09)60829-1 – ident: ref34 – volume: 6 start-page: 677 year: 2011 ident: ref13 article-title: Development of novel drugs for human African trypanosomiasis publication-title: Future Microbiol doi: 10.2217/fmb.11.44 – volume: 113 start-page: 496 year: 2004 ident: ref5 article-title: Human African trypanosomiasis of the CNS: current issues and challenges publication-title: J Clin Invest doi: 10.1172/JCI200421052 – ident: ref6 – volume: 27 start-page: 384 year: 1970 ident: ref24 article-title: The haematocrit centrifuge technique for the diagnosis of African trypanosomiasis publication-title: Acta Trop – volume: 17 ident: ref8 – volume: 11 start-page: 876 year: 2010 ident: ref11 article-title: Diamidines for human African trypanosomiasis publication-title: Curr Opin Investig Drugs – volume: 33 start-page: 1886 year: 2005 ident: ref29 article-title: Unusual dehydroxylation of antimicrobial amidoxime prodrugs by cytochrome b5 and NADH cytochrome b5 reductase publication-title: Drug Metab Dispos – volume: 54 start-page: 2507 year: 2010 ident: ref22 article-title: Novel arylimidamides for treatment of visceral leishmaniasis publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.00250-10 – volume: 47 start-page: 4335 year: 2004 ident: ref25 article-title: O-alkoxyamidine prodrugs of furamidine: in vitro transport and microsomal metabolism as indicators of in vivo efficacy in a mouse model of Trypanosoma brucei rhodesiense infection publication-title: J Med Chem doi: 10.1021/jm030604o – volume: 12 start-page: 562 year: 2012 ident: ref9 article-title: Antiparasitic agents: new drugs on the horizon publication-title: Curr Opin Pharmacol doi: 10.1016/j.coph.2012.05.001 – volume: 337 start-page: 503 year: 2011 ident: ref31 article-title: Mechanisms Underlying Differences in Systemic Exposure of Structurally Similar Active Metabolites: Comparison of Two Preclinical Hepatic Models publication-title: Journal of Pharmacology and Experimental Therapeutics doi: 10.1124/jpet.110.177220 – volume: 34 start-page: 1985 year: 2006 ident: ref17 article-title: CYP4F enzymes are the major enzymes in human liver microsomes that catalyze the O-demethylation of the antiparasitic prodrug DB289 [2,5-bis(4-amidinophenyl)furan-bis-O-methylamidoxime] publication-title: Drug Metab Dispos doi: 10.1124/dmd.106.010587 – volume: 53 start-page: 4185 year: 2009 ident: ref12 article-title: New treatment option for second-stage African sleeping sickness: in vitro and in vivo efficacy of aza analogs of DB289 publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.00225-09 – volume: 41 start-page: 518 year: 2013 ident: ref23 article-title: Compartmental and enzyme kinetic modeling to elucidate the biotransformation pathway of a centrally acting antitrypanosomal prodrug publication-title: Drug Metab Dispos doi: 10.1124/dmd.112.048231 – volume: 6 start-page: 3017 year: 1996 ident: ref28 article-title: Anti-pneumocystis activity of bis-amidoximes and bis-O-alkylamidoximes prodrugs publication-title: Bioorg Med Chem Lett doi: 10.1016/S0960-894X(96)00557-4 – volume: 53 start-page: 953 year: 2009 ident: ref16 article-title: Efficacy of the novel diamidine compound 2,5-Bis(4-amidinophenyl)- furan-bis-O-Methlylamidoxime (Pafuramidine, DB289) against Trypanosoma brucei rhodesiense infection in vervet monkeys after oral administration publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.00831-08 – volume: 35 start-page: 955 year: 2007 ident: ref32 article-title: Pharmacokinetics and metabolism of the prodrug DB289 (2,5-bis[4-(N-methoxyamidino)phenyl]furan monomaleate) in rat and monkey and its conversion to the antiprotozoal/antifungal drug DB75 (2,5-bis(4-guanylphenyl)furan dihydrochloride) publication-title: Drug Metab Dispos doi: 10.1124/dmd.106.013391 – volume: 16 start-page: 354 year: 2010 ident: ref3 article-title: Human African Trypanosomiasis in Areas without Surveillance publication-title: Emerging Infectious Diseases doi: 10.3201/eid1602.090967 – volume: 90 start-page: 999 year: 2008 ident: ref10 article-title: Antiparasitic compounds that target DNA publication-title: Biochimie doi: 10.1016/j.biochi.2008.02.017 – volume: 130 start-page: 416 year: 2012 ident: ref21 article-title: A Mouse Diversity Panel Approach Reveals the Potential for Clinical Kidney Injury Due to DB289 Not Predicted by Classical Rodent Models publication-title: Toxicol Sci doi: 10.1093/toxsci/kfs238 – volume: 39 start-page: 351 year: 2004 ident: ref27 article-title: Metabolites of an orally active antimicrobial prodrug, 2,5-bis(4-amidinophenyl)furan-bis-O-methylamidoxime, identified by liquid chromatography/tandem mass spectrometry publication-title: J Mass Spectrom doi: 10.1002/jms.591 – reference: 4632237 - CA Cancer J Clin. 1972 Nov-Dec;22(6):360-3 – reference: 15103648 - J Mass Spectrom. 2004 Apr;39(4):351-60 – reference: 15294005 - J Med Chem. 2004 Aug 12;47(17):4335-8 – reference: 19064893 - Antimicrob Agents Chemother. 2009 Mar;53(3):953-7 – reference: 22433595 - Euro Surveill. 2012;17(10). pii: 20111 – reference: 16997912 - Drug Metab Dispos. 2006 Dec;34(12):1985-94 – reference: 17360833 - Drug Metab Dispos. 2007 Jun;35(6):955-67 – reference: 7391131 - J Cell Biol. 1980 Jun;85(3):501-15 – reference: 18846231 - PLoS Negl Trop Dis. 2008;2(5):e238 – reference: 20368397 - Antimicrob Agents Chemother. 2010 Jun;54(6):2507-16 – reference: 4396363 - Acta Trop. 1970;27(4):384-6 – reference: 22652215 - Curr Opin Pharmacol. 2012 Oct;12(5):562-6 – reference: 14561095 - J Med Chem. 2003 Oct 23;46(22):4761-9 – reference: 10070249 - World Health Organ Tech Rep Ser. 1998;881:I-VI, 1-114 – reference: 15234662 - Acta Trop. 2004 Jul;91(2):131-43 – reference: 21402852 - Antimicrob Agents Chemother. 2011 May;55(5):2352-61 – reference: 20961469 - Parasitology. 2010 Dec;137(14):1987-94 – reference: 16135190 - Trop Med Int Health. 2005 Sep;10(9):840-9 – reference: 19833383 - Lancet. 2010 Jan 9;375(9709):148-59 – reference: 21151878 - PLoS Negl Trop Dis. 2010;4(12):e906 – reference: 20113585 - Emerg Infect Dis. 2010 Feb;16(2):354-6 – reference: 19620327 - Antimicrob Agents Chemother. 2009 Oct;53(10):4185-92 – reference: 23223498 - Drug Metab Dispos. 2013 Feb;41(2):518-28 – reference: 21320872 - J Pharmacol Exp Ther. 2011 May;337(2):503-12 – reference: 20721830 - Curr Opin Investig Drugs. 2010 Aug;11(8):876-83 – reference: 22940726 - Toxicol Sci. 2012 Dec;130(2):416-26 – reference: 18343228 - Biochimie. 2008 Jul;90(7):999-1014 – reference: 22848769 - PLoS Negl Trop Dis. 2012;6(7):e1734 – reference: 16019947 - Xenobiotica. 2005 Mar;35(3):211-26 – reference: 21707314 - Future Microbiol. 2011 Jun;6(6):677-91 – reference: 16131524 - Drug Metab Dispos. 2005 Dec;33(12):1886-93 – reference: 14966556 - J Clin Invest. 2004 Feb;113(4):496-504 |
| SSID | ssj0059581 |
| Score | 2.1275053 |
| Snippet | There are no oral drugs for human African trypanosomiasis (HAT, sleeping sickness). A successful oral drug would have the potential to reduce or eliminate the... There are no oral drugs for human African trypanosomiasis (HAT, sleeping sickness). A successful oral drug would have the potential to reduce or eliminate... |
| SourceID | plos doaj pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | e2230 |
| SubjectTerms | Administration, Oral African trypanosomiasis Amidines - adverse effects Amidines - pharmacokinetics Amidines - pharmacology Animals Antiprotozoal Agents - administration & dosage Antiprotozoal Agents - adverse effects Antiprotozoal Agents - pharmacokinetics Antiprotozoal Agents - pharmacology Cercopithecus aethiops Disease Models, Animal Drug dosages Drug therapy Infections Male Medicine Oral medication Pharmaceutical industry Pharmacokinetics Plasma Testing Treatment Outcome Trypanosoma Trypanosomiasis, African - drug therapy |
| SummonAdditionalLinks | – databaseName: DOAJ (Directory of Open Access Journals) dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELbQHhAXxLuBAkZC4tK0TmzH9rEFqgqpXKBSb5GfYkVJVk2KtEf-OWM7u9ogRC9c9mCPpc3MeDKfMvMNQm85E955bkrIJgCgcACsStShVMzx4CoSQgKK55-bswv26ZJf7oz6ijVhmR44K-6I0loZagiVzjBbBWOMDrY2ntEm3s0YfYkiGzCVYzBXPI0nhewkdlzVYmqao6I6mmx0uOpGd5j4X2IF9M5LKXH3byP0YnXVD39LP_-sotx5LZ0-QPenfBIf5-d4iO747hG6ez59MX-Mfn3RwY_rA7yaOKq_wzLIHmDdOewjgYS2azzkckLcBxxb9vGHE9lIvOywxmEJCSIIQODBP2N95IjBdeHu4zRFJx5Jg_5wHjnU4fF6DSGmH_ofSz0shyfo4vTj1_dn5TR2obRNrcayCcRVLHhZuyo0wgECEcRAKsGC8_DDrJDWghmU99LG3lyrmWbwtyRvjAj0KVp0fef3EAY0wrXgTGtBGbFcEUs0c8ESqqSQvEB0o_fWTpzkcTTGVZs-tAnAJlmNbbRWO1mrQOX21CpzctwifxJNupWNjNppAfysnfysvc3PCvQ6OkSb21O3caE9plTUMlI6F-hdkoiRAR4CrJcbHEAVkWNrJrk_k4QbbWfbe9HpNs8yADxL1HqyZgV6s3HENp6KFXKd729AhjYgQAAe_ksG4EBNhVIFepadd6sUWI4TpGBHzNx6prX5Trf8lvjIaSMAN_Pn_0PNL9C9Og8cKUm1jxbj9Y1_CWnfaF6lG_4bLgVYXw priority: 102 providerName: Directory of Open Access Journals |
| Title | Safety, Pharmacokinetic, and Efficacy Studies of Oral DB868 in a First Stage Vervet Monkey Model of Human African Trypanosomiasis |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/23755309 https://www.proquest.com/docview/1366820974 https://www.proquest.com/docview/1399923799 https://pubmed.ncbi.nlm.nih.gov/PMC3674995 https://doaj.org/article/3329b3b038db4c1fbbbafc2be436adde http://dx.doi.org/10.1371/journal.pntd.0002230 |
| Volume | 7 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3Nb9MwFLdGJyEuiO8FRjESEpelSmI7dg4IraPVhLQxwYp6ixzHhoiSlCaT6JH_nGcnjQgaH5cc7Ocmfn5-fr_a_j2EXjDKda5Z5kM0AQCFAWBNeGT8hObM5GFgjAOKZ-fx6YK-XbLlHtrlbO0UWF8L7Ww-qcVmNfn-bfsaJvwrl7WBh7tGk3XZ5BPH6EIAxO-7HSN7mI_2-wosYS5tKUQt9iZWxLvLdH_6lcFi5Tj9e889Wq-q-rqw9PfTlb8sV_M76HYXZ-Lj1jDuoj1d3kM3z7qd9PvoxwdpdLM9whcdd_UXKAbZIyzLHM8ssYRUW9wdM8SVwe_gLfjNVMQCFyWWeF5A4AgC4JDwR3tussHgIMAnYJtfbWWbuB0C3KYiKvHlZguup6qrr4Wsi_oBWsxnlyenfpeOwVdxlDR-bII8pEaLKA9NzHNAJjzIIMSgJtfwoIoLpbJMJloLZe_sKkklhc8SLM64IQ_RqKxKfYAwoBQmOaNSckIDxZJABZLmRgUkEVwwD5Gd3lPVcZXblBmr1G3AccAsrRpTO1ppN1oe8vtW65ar4x_yUzukvaxl2nYF1eZT2k3clJAoyUgWEJFnVIUmgw4aFWWaktiuDR56Zg0iba-t9v4iPSaER8JSPXvopZOwNgydgNFrLz6AKiz31kDycCAJM10Nqg-s0e36UgNsc5R7IqIeer4zxNS2sifnSl1dgQyJQSAA2Pg3GYAJEeFJ4qFHrfH2SoFim1kKavjArAdaG9aUxWfHU05iDniaPf6P9z5Bt6I2z4gfhIdo1Gyu9FOI9ppsjG7wJYenOAnHaH86O794P3b_nIzd1P4JzRdYdw |
| linkProvider | Scholars Portal |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Safety%2C+Pharmacokinetic%2C+and+Efficacy+Studies+of+Oral+DB868+in+a+First+Stage+Vervet+Monkey+Model+of+Human+African+Trypanosomiasis&rft.jtitle=PLoS+neglected+tropical+diseases&rft.au=Thuita%2C+John+K&rft.au=Wolf%2C+Kristina+K&rft.au=Murilla%2C+Grace+A&rft.au=Liu%2C+Qiang&rft.date=2013-06-01&rft.issn=1935-2727&rft.eissn=1935-2735&rft.volume=7&rft.issue=6&rft_id=info:doi/10.1371%2Fjournal.pntd.0002230&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1935-2735&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1935-2735&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1935-2735&client=summon |